Senate committee approves Board of Pharmacy rule rewrite but strikes labeling subsections after compounding debate

The Senate Health and Welfare Committee on Jan. 14 approved a pending rewrite of the Idaho State Board of Pharmacy rules (docket 24-3601-2402) while removing two labeling subsections related to distribution of compounded products.

The committee’s action follows a presentation from Nikki Chopsky, bureau chief for Health Professions at the Division of Occupational and Professional Licenses, who said the board conducted multiple public meetings and stakeholder negotiations as part of a zero‑based review (ZBR) that produced more than 35 changes to the chapter. The changes consolidate definitions, remove duplicative language that has been moved to statute following last year’s House Bill 527, and reorganize licensure, practice standards, compounding, controlled substances and prescription monitoring rules.

Why it matters: The removed subsections concern labeling and distribution of compounded drug products, an area several stakeholders and committee members said could affect access and business models for companies that compound drugs. Board staff told the committee the topic is legally unsettled at the federal level because the Food and Drug Administration has a draft guidance document (marked draft and non‑binding) and several recent lawsuits have affected the regulatory landscape.

Chopsky told senators the board had invited the stakeholders raising concerns to participate and that the board intends to continue working with them: “The board stands committed to working transparently with these stakeholders and others for a workable solution in an environment that is unsettled at this time.”

Discussion and votes: The committee first took no action on the temporary rule docket 24-3601-2401 (the temporary rules issued earlier), a move Chopsky said was acceptable because stakeholder feedback prompted removal of an incomplete list from the temporary rules. Later the committee considered the pending rewrite (24-3601-2402). Senator Lenny offered and successfully carried a substitute motion to approve the pending docket while striking the subsections identified as 214 E(i) and 214 E(ii) — the two labeling/distribution lines at issue. The committee recorded a roll call tally of 7‑yes, 2‑no on the substitute motion; the committee then adopted the pending docket with that exception and moved on to the next agenda item.

What was not decided: The Board of Pharmacy maintained the broader compounding and labeling language in the pending chapter except for the struck subsections. Chopsky said Idaho has legal pathways for compounded products to be labeled and used in state and that Idaho has its own compounding rules that predate some USP chapters used elsewhere. She also said the board did not incorporate the FDA draft guidance into rule because it is non‑binding and marked draft.

Stakeholder positions: Chopsky said industry participants included the two state pharmacy associations, national associations, the Idaho Medical Association, payers and individual practitioners. She said two stakeholder groups raised late concerns about subsection 40605 (now relocated in pending rule text), prompting outreach and further discussions with the board.

Next steps: With the committee’s approval (with the two subsections removed), the pending rule chapter will proceed as revised. The board and division said they will continue stakeholder engagement if federal guidance or litigation changes the regulatory context.